ALK and non-small cell lung carcinoma: Targeted therapies (EGFR/ALK-TKIs) and ICIs have revolutionized treatment of advanced NSCLC and about 25% of NSCLC patients can harbor EGFR and ALK mutations9, but these were not approved for early stage NSCLC during periods of our study.